Ugur Sahin Sells 15,000 Shares of BioNTech (NASDAQ:BNTX) Stock

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 15,000 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $96.09, for a total value of $1,441,350.00. Following the sale, the chief executive officer owned 553,209 shares in the company, valued at approximately $53,157,852.81. This represents a 2.64% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $96.49, for a total value of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total value of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $96.93, for a total value of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total value of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The shares were sold at an average price of $97.78, for a total value of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The shares were sold at an average price of $99.20, for a total value of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The stock was sold at an average price of $103.52, for a total transaction of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total transaction of $4,628,250.00.

BioNTech Price Performance

Shares of BNTX stock traded down $0.86 during trading hours on Wednesday, reaching $95.83. The stock had a trading volume of 407,411 shares, compared to its average volume of 1,104,336. The stock’s fifty day simple moving average is $97.13 and its 200 day simple moving average is $95.10. The firm has a market capitalization of $24.23 billion, a PE ratio of -12.24 and a beta of 1.29. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last posted its earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.40) by ($0.13). The firm had revenue of $122.31 million during the quarter, compared to analysts’ expectations of $180.18 million. BioNTech had a negative return on equity of 6.86% and a negative net margin of 63.54%.The business’s revenue for the quarter was down 59.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.60) earnings per share. On average, equities research analysts predict that BioNTech SE Sponsored ADR will post -6.33 EPS for the current year.

Institutional Investors Weigh In On BioNTech

Several hedge funds have recently added to or reduced their stakes in the company. Engineers Gate Manager LP lifted its position in BioNTech by 17.3% in the 2nd quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock worth $1,157,000 after buying an additional 1,833 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in BioNTech during the second quarter valued at approximately $39,000. Nykredit A S purchased a new position in shares of BioNTech during the second quarter worth approximately $293,000. B. Metzler seel. Sohn & Co. AG lifted its holdings in shares of BioNTech by 66.7% in the 2nd quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock worth $1,020,000 after acquiring an additional 4,390 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in shares of BioNTech in the 2nd quarter worth approximately $2,520,000. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on the company. Wall Street Zen lowered BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. UBS Group reissued a “buy” rating on shares of BioNTech in a report on Wednesday. BMO Capital Markets cut shares of BioNTech from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $128.00 to $105.00 in a research report on Tuesday, September 8th. Berenberg Bank set a $140.00 target price on shares of BioNTech in a research note on Wednesday. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of BioNTech in a research report on Friday, June 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.